Oral selumetinib (AstraZeneca) reduces tumor volume in children with inoperable plexiform neurofibroma, benign tumors of peripheral nerves related to neurofibromatosis type 1 (NF1), with acceptable ...

Gomekli (mirdametinib) is the first treatment that is FDA approved for both adults and children with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PN). Selumetinib, a drug that ...

A genetic disease that causes tumors to form on nerves has a new FDA-approved treatment, a SpringWorks Therapeutics drug that can address a wider range of patients than the AstraZeneca product that ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Gomekli is the first treatment of its kind to be ...

Selumetinib's approval now includes children as young as 1 year old with NF1 and symptomatic, inoperable plexiform neurofibromas. The drug targets the RAS/MEK/ERK pathway, providing a non-surgical ...

It can spawn tumors throughout the nervous system and bone deformities that riddle the whole body with pain. One of the most common rare diseases in the world, the genetic condition neurofibromatosis ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

The Children’s Tumor Foundation is raising awareness about a group of incurable genetic conditions called neurofibromatosis, or NF. Neurofibromatosis is a group of genetic conditions that causes ...